Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues

被引:32
作者
Cao, Y
Becker, C
Lundwall, Å
Christensson, A
Gadaleanu, V
Lilja, H
Bjartell, A [1 ]
机构
[1] Lund Univ, Malmo Univ Hosp, Dept Urol, SE-20502 Malmo, Sweden
[2] Lund Univ, Malmo Univ Hosp, Dept Clin Chem, SE-20502 Malmo, Sweden
[3] Lund Univ, Malmo Univ Hosp, Dept Nephrol & Transplantat, SE-20502 Malmo, Sweden
[4] Lund Univ, Malmo Univ Hosp, Dept Pathol, SE-20502 Malmo, Sweden
[5] Mem Sloan Kettering Canc Ctr, Dept Clin Labs Urol & Med, New York, NY 10021 USA
关键词
serpin; prostate-specific antigen; prostate cancer; human glandular kallikrein-2; tissue microarray; cell lines;
D O I
10.1002/pros.10296
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Protein C inhibitor (PCI) occurs at high concentration in seminal plasma, and inhibits human glandular kallikrein-2 and, less readily, prostate-specific antigen. Previous studies have localized PCI in the male genital tract. Here we have performed a detailed investigation of PCI expression in the prostatic tissues, metastases, and cell lines. METHODS. Immunohistochemistry, in situ hybridization, and Western blotting were used to study prostatic tissues, metastases, and PC-3, DU-145, and LNCaP cells. RESULTS. PCI was immunolocalized in tissue microarray spots with BPH epithelium (detection rate 100%), PIN lesions (100%), tumors (96%), metastases (88%), and in all cell lines. ISH and WB supported the findings. CONCLUSIONS. PCI is widely expressed in benign prostatic epithelium, and may act as a local regulator of enzymatic activity in seminal fluid, of importance for normal sperm function. Lack of PCI expression in a subpopulation of high-grade tumor cells in combination with maintained protease expression may facilitate invasive growth patterns. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:196 / 204
页数:9
相关论文
共 37 条
[1]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[2]  
2-Z
[3]   PRODUCTION OF ALPHA-1-ANTICHYMOTRYPSIN BY PSA-CONTAINING CELLS OF HUMAN PROSTATE EPITHELIUM [J].
BJARTELL, A ;
ABRAHAMSSON, PA ;
BJORK, T ;
DISANTAGNESE, A ;
MATIKAINEN, MT ;
LILJA, H .
UROLOGY, 1993, 42 (05) :502-510
[4]   ALPHA(1)-ANTICHYMOTRYPSIN PRODUCTION IN PSA-PRODUCING CELLS IS COMMON IN PROSTATE-CANCER BUT RARE IN BENIGN PROSTATIC HYPERPLASIA [J].
BJORK, T ;
BJARTELL, A ;
ABRAHAMSSON, PA ;
HULKKO, S ;
DISANTAGNESE, A ;
LILJA, H .
UROLOGY, 1994, 43 (04) :427-434
[5]   Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2 [J].
Bourgeois, L ;
BrillardBourdet, M ;
Deperthes, D ;
Juliano, MA ;
Juliano, L ;
Tremblay, RR ;
Dube, JY ;
Gauthier, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (47) :29590-29595
[6]   Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2 [J].
Cao, Y ;
Lundwall, Å ;
Gadaleanu, V ;
Lilja, H ;
Bjartell, A .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (06) :2053-2063
[7]   HIGH-LEVEL OF EXPRESSION IN THE PROSTATE OF A HUMAN GLANDULAR KALLIKREIN MESSENGER-RNA RELATED TO PROSTATE-SPECIFIC ANTIGEN [J].
CHAPDELAINE, P ;
PARADIS, G ;
TREMBLAY, RR ;
DUBE, JY .
FEBS LETTERS, 1988, 236 (01) :205-208
[8]   COMPLEX-FORMATION BETWEEN PROTEIN-C INHIBITOR AND PROSTATE-SPECIFIC ANTIGEN IN-VITRO AND IN HUMAN SEMEN [J].
CHRISTENSSON, A ;
LILJA, H .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 220 (01) :45-53
[9]   IMMUNOENZYMATIC LABELING OF MONOCLONAL-ANTIBODIES USING IMMUNE-COMPLEXES OF ALKALINE-PHOSPHATASE AND MONOCLONAL ANTI-ALKALINE PHOSPHATASE (APAAP COMPLEXES) [J].
CORDELL, JL ;
FALINI, B ;
ERBER, WN ;
GHOSH, AK ;
ABDULAZIZ, Z ;
MACDONALD, S ;
PULFORD, KAF ;
STEIN, H ;
MASON, DY .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1984, 32 (02) :219-229
[10]   Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma [J].
Deperthes, D ;
Chapdelaine, P ;
Tremblay, RR ;
Brunet, C ;
Berton, J ;
Hebert, J ;
Lazure, C ;
Dube, JY .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1995, 1245 (03) :311-316